AU2003251397B2 - Compositions and methods for liver growth and liver protection - Google Patents

Compositions and methods for liver growth and liver protection Download PDF

Info

Publication number
AU2003251397B2
AU2003251397B2 AU2003251397A AU2003251397A AU2003251397B2 AU 2003251397 B2 AU2003251397 B2 AU 2003251397B2 AU 2003251397 A AU2003251397 A AU 2003251397A AU 2003251397 A AU2003251397 A AU 2003251397A AU 2003251397 B2 AU2003251397 B2 AU 2003251397B2
Authority
AU
Australia
Prior art keywords
liver
vegf
flt
fit
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003251397A
Other languages
English (en)
Other versions
AU2003251397A1 (en
Inventor
Napoleone Ferrara
Kenneth J. Hillan
Jennifer Le Couter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2003251397A1 publication Critical patent/AU2003251397A1/en
Application granted granted Critical
Publication of AU2003251397B2 publication Critical patent/AU2003251397B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003251397A 2002-06-05 2003-06-05 Compositions and methods for liver growth and liver protection Ceased AU2003251397B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38663702P 2002-06-05 2002-06-05
US60/386,637 2002-06-05
PCT/US2003/017591 WO2003103581A2 (en) 2002-06-05 2003-06-05 Compositions and methods for liver growth and liver protection

Publications (2)

Publication Number Publication Date
AU2003251397A1 AU2003251397A1 (en) 2003-12-22
AU2003251397B2 true AU2003251397B2 (en) 2009-10-01

Family

ID=29736189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251397A Ceased AU2003251397B2 (en) 2002-06-05 2003-06-05 Compositions and methods for liver growth and liver protection

Country Status (7)

Country Link
US (2) US7700571B2 (https=)
EP (2) EP2430923A1 (https=)
JP (2) JP5111729B2 (https=)
AU (1) AU2003251397B2 (https=)
CA (1) CA2486270C (https=)
IL (2) IL165392A0 (https=)
WO (1) WO2003103581A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP5111729B2 (ja) 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
ATE548447T1 (de) * 2004-01-14 2012-03-15 Novahep Ab Menschlicher hepatische vorläuferzellen und verfahren zur verwendung davon
US8070703B2 (en) * 2004-03-10 2011-12-06 Vision Quest Industries Incorporated Electrically stimulating orthotic device and segmented liner
WO2006014678A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
EP2447281B1 (en) 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
EP1904095B1 (en) 2005-06-30 2013-05-29 VIB, vzw Treatment of liver cirrhosis and its complications
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
AU2007230580A1 (en) * 2006-03-27 2007-10-04 Genentech, Inc. Methods for treating kidney disorders
US8685730B2 (en) * 2006-05-02 2014-04-01 Wisconsin Alumni Research Foundation Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
CN101250498B (zh) * 2008-04-07 2010-06-09 南通大学附属医院 用载肝细胞生长因子聚乳酸-o-羧甲基壳聚糖纳米粒子的肝细胞培养方法
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
ES2788300T3 (es) * 2010-11-09 2020-10-21 Univ Cornell Regeneración hepática
ES2424476T3 (es) * 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
KR102461927B1 (ko) * 2016-02-17 2022-10-31 차의과학대학교 산학협력단 이식용 줄기세포 및 이를 포함하는 혈관신생의 유도 또는 촉진을 위한 이식용 약학 조성물
CN114224893B (zh) * 2022-01-25 2023-06-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 喹唑啉衍生物在制备防治砷致肝损伤药物中的用途
CN116869986B (zh) * 2023-07-13 2025-12-02 南方医科大学 β-羟基丁酸在制备促进肝细胞增殖和肝脏再生产品方面的应用
TWI909652B (zh) 2023-08-31 2025-12-21 日商肽夢想股份有限公司 具有ｖｅｇｆｒ－２促效劑活性的肽複合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002333622A1 (en) * 2001-10-05 2003-04-22 Collins And Aikman Products Co. Sound attenuating material for use within vehicles and methods of making same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US6107046A (en) 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
DE69628652T3 (de) * 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2265931T3 (es) 1999-04-16 2007-03-01 Genentech, Inc. Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos.
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US20020164310A1 (en) * 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
JP5111729B2 (ja) * 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002333622A1 (en) * 2001-10-05 2003-04-22 Collins And Aikman Products Co. Sound attenuating material for use within vehicles and methods of making same

Also Published As

Publication number Publication date
EP1531676B1 (en) 2015-07-22
JP2005534648A (ja) 2005-11-17
EP1531676A4 (en) 2009-06-17
EP2430923A1 (en) 2012-03-21
HK1076227A1 (en) 2006-01-13
WO2003103581A3 (en) 2004-04-15
CA2486270A1 (en) 2003-12-18
EP1531676A2 (en) 2005-05-25
US20070122394A1 (en) 2007-05-31
CA2486270C (en) 2015-07-28
WO2003103581A2 (en) 2003-12-18
US7700571B2 (en) 2010-04-20
AU2003251397A1 (en) 2003-12-22
US20040170613A1 (en) 2004-09-02
IL165392A (en) 2015-11-30
JP2010159266A (ja) 2010-07-22
JP5111729B2 (ja) 2013-01-09
US7709455B2 (en) 2010-05-04
IL165392A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
AU2003251397B2 (en) Compositions and methods for liver growth and liver protection
Warren et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Mise et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
Ferrara The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara et al. The biology of VEGF and its receptors
US5654404A (en) Protection against liver damage by HGF
Niu et al. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy
Neufeld et al. Vascular endothelial growth factor and its receptors
Puolakkainen et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis
Feldman et al. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells
Zhu et al. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics
US20020102260A1 (en) Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
List et al. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase–dependent clonogenic response in acute myeloid leukemia cells
US7354582B2 (en) Use of VEGF antagonists for the treatment of malignant gliomas
CA2909689A1 (en) Methods of treating cancer
Ton et al. Resistance to anti-VEGF agents
Shan et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival
WO2007022273A2 (en) Vegf-activated fas ligands
Bruce et al. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
Guo et al. Regulation of angiogenesis in human cancer via vascular endothelial growth factor receptor-2 (VEGFR-2)
HK1076227B (en) Compositions and methods for liver growth and liver protection
Ribatti From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials
Michalopoulos Liver regeneration
KR20040004681A (ko) 혈관재생 요법
Donovan Vascular endothelial growth factor in breast cancer and novel anti-angiogenic mechanisms of tamoxifen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired